Related Topics



Genea Gets Orphan Drug Designation

Genea Biocells Announces FDA Orphan Drug Designation for GBC0905 For The Treatment Of  Facioscapulohumeral Muscular Dystrophy (FSHD) San Diego (CA), May 30, 2018 -- Genea Biocells, a preclinical-stage company focused on...

Read More

Powering 3-D Muscle Models

Genea Biocells’ Media: Powering 3-D Muscle Models and Beyond.   Genea Biocells enabled muscle A recent publication1 details the in vitro fabrication of 3-D skeletal muscle from human induced pluripotent stem cells (hiPSC)...

Read More

Skeletal Muscle Seminar Series SBP

Genea Biocells is co-sponsoring the "2018 SD Skeletal Muscle Seminar Series" with Sanford Burnham Prebys. The goal of these FREE monthly talks is to promote skeletal muscle research, enhance its...

Read More

Genea Sponsors FSHD Research Mtg.

Genea Biocells is proud to be one of the sponsors of the 2018 FSHD International Research Conference being held at the Flamingo in Las Vegas June 8th through the 10th....

Read More


As Genea Biocells is establishing itself in the San Diego biotech community, we are actively taking steps to differentiate  ourselves from our parent company, Genea Fertility, located in Australia.  As...

Read More

Genea Biocells partners with AMSBIO

Genea Biocells (San Diego, USA) has partnered with AMSBIO for global distribution to the academic community for its leading-edge skeletal muscle differentiation kits.   For more information please visit:  AMSBIO and Genea Biocells...

Read More